• Mashup Score: 1

    Dr. Kim Eagle, Dr. Deepak Bhatt, and Dr. Payal Kohli look back on Day 1 of ACC.201 late-breaking science and featured clinical research, including LAAOS III (0:38), ATLANTIS (4:07), ADAPTABLE (8:02), EXPLORER-HCM (13:25), and PARADISE-MI (16:59). Clinical Topics: Acute Coronary Syndromes, Anticoagulation Management, Arrhythmias and Clinical EP, Atherosclerotic Disease (CAD/PAD),…

    Tweet Tweets with this article
    • A new video featuring @keaglemd, @DLBHATTMD, and @payalkohlimd reflects on late-breaking science and featured clinical research from day one of #ACC21, including #LAAOS III, #ATLANTIS, #ADAPTABLE, EXPLORER-HCM, and #PARADISEMI! Watch it now: https://t.co/ySSemjqnYF https://t.co/BnJE33DKG0

  • Mashup Score: 3

    Dr. Kim Eagle, Dr. Deepak Bhatt, and Dr. Payal Kohli look back on Day 1 of ACC.201 late-breaking science and featured clinical research, including LAAOS III (0:38), ATLANTIS (4:07), ADAPTABLE (8:02), EXPLORER-HCM (13:25), and PARADISE-MI (16:59). Clinical Topics: Acute Coronary Syndromes, Anticoagulation Management, Arrhythmias and Clinical EP, Atherosclerotic Disease (CAD/PAD),…

    Tweet Tweets with this article
    • Catch up on the highlights from day 1 of #ACC21! @keaglemd, @DLBHATTMD, and @payalkohlimd look back on late-breaking science and featured clinical research, including #LAAOS III, #ATLANTIS, #ADAPTABLE, EXPLORER-HCM, and #PARADISEMI: https://t.co/szQxgLxLAH https://t.co/KXsO9kD2cV

  • Mashup Score: 6

    (UPDATED) The open-label study had a high crossover rate, throwing some doubt on the reliability of the results, say experts.

    Tweet Tweets with this article
    • 2. Dont forget to get all the news from #ACC21 and expert insight from @TCTMD with #ADAPTABLE https://t.co/819cqpZrYG AND #ATLANTIS https://t.co/5tsp1TI4pf @michaelTCTMD @JSillerMatula @Uqayyum123 @DrAmirKaki @SukhNijjer @rwyeh @MedCrisis @ShrillaB @yourheartdoc1 @nolanjimradial https://t.co/w7XFKqv2VC

  • Mashup Score: 2

    Future research needs to consider the longer-term impact of thrombus and whether certain patient subsets could benefit.

    Tweet Tweets with this article
    • #ATLANTIS RCT @ACCinTouch #ACC21 Apixaban no benefit over SOC in #TAVR. What will everyone do now? @djc795 @DrMoritzWvB @SachinGoelMD @NimeshDesaiMD @modine_thomas @DFCapodanno @DLBHATTMD @willsuh76 @PhilGenereuxMD @TCTMD Nice article https://t.co/ZIFJUBzKyC https://t.co/XJAxkfNN7z